Effect of parathyroid hormone therapy for mediation related osteonecrosis of the jaw.

Effect of parathyroid hormone therapy for mediation related osteonecrosis of the jaw. - Drug therapy for MRONJ

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024896

Enrollment

Registered

2016-11-18

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medication related osteonecrosis of the jaw

Interventions

Parathyroid hormone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Osteonecrosis of the jaw by using osteoporosis drug

Exclusion criteria

Exclusion criteria: Patients with malignant cancer in the bone

Design outcomes

Primary

Measure	Time frame
Spontaneous sequestration separation 6 months after starting drug therapy.	—

Countries

Japan

Contacts

Public ContactMakoto Hirota

Yokohama City University Oral and Maxillofacial Surgery

mhirota@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026